US09062X1037 - Common Stock

**BIIB** gets a fundamental rating of **5** out of 10. The analysis compared the fundamentals against 599 industry peers in the **Biotechnology** industry. While **BIIB** belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. **BIIB** has a valuation in line with the averages, but it does not seem to be growing.

In the past year **BIIB** had a positive cash flow from operations.

In the past 5 years **BIIB** has always been profitable.

With an excellent **Return On Assets** value of **4.33%**, **BIIB** belongs to the best of the industry, outperforming **95.44%** of the companies in the same industry.

With an excellent **Return On Equity** value of **7.85%**, **BIIB** belongs to the best of the industry, outperforming **95.44%** of the companies in the same industry.

With an excellent **Return On Invested Capital** value of **7.53%**, **BIIB** belongs to the best of the industry, outperforming **95.95%** of the companies in the same industry.

The 3 year average ROIC (**11.97%**) for **BIIB** is well above the current ROIC(**7.53%**). The reason for the recent decline needs to be investigated.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 4.33% | ||

ROE | 7.85% | ||

ROIC | 7.53% |

ROA(3y)7.75%

ROA(5y)12.23%

ROE(3y)14.96%

ROE(5y)25.28%

ROIC(3y)11.97%

ROIC(5y)17.09%

The **Profit Margin** of **BIIB** (**11.81%**) is better than **96.28%** of its industry peers.

The **Operating Margin** of **BIIB** (**20.84%**) is better than **96.96%** of its industry peers.

With an excellent **Gross Margin** value of **74.24%**, **BIIB** belongs to the best of the industry, outperforming **84.80%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | 20.84% | ||

PM (TTM) | 11.81% | ||

GM | 74.24% |

OM growth 3Y-17.42%

OM growth 5Y-15.65%

PM growth 3Y-26.52%

PM growth 5Y-18.55%

GM growth 3Y-4.99%

GM growth 5Y-3.01%

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), **BIIB** is creating some value.

The number of shares outstanding for **BIIB** has been increased compared to 1 year ago.

The debt/assets ratio for **BIIB** is higher compared to a year ago.

With a decent **Altman-Z score** value of **3.30**, **BIIB** is doing good in the industry, outperforming **72.13%** of the companies in the same industry.

The **Debt to FCF ratio** of **BIIB** (**5.61**) is better than **94.76%** of its industry peers.

A Debt/Equity ratio of **0.46** indicates that **BIIB** is not too dependend on debt financing.

With a **Debt to Equity ratio** value of **0.46**, **BIIB** is not doing good in the industry: **75.00%** of the companies in the same industry are doing better.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.46 | ||

Debt/FCF | 5.61 | ||

Altman-Z | 3.3 |

ROIC/WACC0.71

WACC10.65%

Looking at the **Current ratio**, with a value of **2.00**, **BIIB** is doing worse than **79.39%** of the companies in the same industry.

A Quick Ratio of **1.26** indicates that **BIIB** should not have too much problems paying its short term obligations.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 2 | ||

Quick Ratio | 1.26 |

The earnings per share for **BIIB** have decreased strongly by **-18.27%** in the last year.

Looking at the last year, **BIIB** shows a decrease in **Revenue**. The Revenue has decreased by **-3.32%** in the last year.

The **Revenue** has been decreasing by **-6.07%** on average over the past years.

EPS 1Y (TTM)-18.27%

EPS 3Y-22.83%

EPS 5Y-10.49%

EPS growth Q2Q-18.52%

Revenue 1Y (TTM)-3.32%

Revenue growth 3Y-9.9%

Revenue growth 5Y-6.07%

Revenue growth Q2Q-6.2%

The **Earnings Per Share** is expected to grow by **9.22%** on average over the next years. This is quite good.

The **Revenue** is expected to grow by **2.13%** on average over the next years.

EPS Next Y6.24%

EPS Next 2Y11.8%

EPS Next 3Y10.09%

EPS Next 5Y9.22%

Revenue Next Year-2.16%

Revenue Next 2Y0.26%

Revenue Next 3Y0.93%

Revenue Next 5Y2.13%

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

A **Price/Earnings** ratio of **14.81** indicates a correct valuation of **BIIB**.

Compared to an average S&P500 **Price/Earnings** ratio of **26.35**, **BIIB** is valued a bit cheaper.

97.64% of the companies in the same industry are more expensive than **BIIB**, based on the **Price/Forward Earnings** ratio.

The average S&P500 **Price/Forward Earnings** ratio is at **21.63**. **BIIB** is valued slightly cheaper when compared to this.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 14.81 | ||

Fwd PE | 13.94 |

Compared to the rest of the industry, the **Enterprise Value to EBITDA** ratio of **BIIB** indicates a rather cheap valuation: **BIIB** is cheaper than 96.11% of the companies listed in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | 26.18 | ||

EV/EBITDA | 15.03 |

The high **PEG Ratio(NY)**, which compensates the Price/Earnings for growth, indicates **BIIB** does not grow enough to justify the current Price/Earnings ratio.

PEG (NY)2.37

PEG (5Y)N/A

EPS Next 2Y11.8%

EPS Next 3Y10.09%

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

**BIOGEN INC**

NASDAQ:BIIB (2/23/2024, 7:00:01 PM)

After market: 223.82 +0.5 (+0.22%)**223.32**

**+0.84 (+0.38%) **

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap32.36B

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 14.81 | ||

Fwd PE | 13.94 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)2.37

PEG (5Y)N/A

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 4.33% | ||

ROE | 7.85% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | 20.84% | ||

PM (TTM) | 11.81% | ||

GM | 74.24% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.37

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.46 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 2 | ||

Quick Ratio | 1.26 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-18.27%

EPS 3Y-22.83%

EPS 5Y

EPS growth Q2Q

EPS Next Y6.24%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-3.32%

Revenue growth 3Y-9.9%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y